Annovis Bio Inc. (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company, has priced an underwritten public offering that is expected to raise approximately $21 million in gross proceeds. The offering consists of 19 million common shares, pre-funded warrants to purchase up to 2 million shares, and accompanying warrants to purchase up to 21 million shares. The combined offering price is $1 per common share and accompanying warrant, or $0.9999 per pre-funded warrant and accompanying warrant. The warrants have an exercise price of $1 per share and expire five years after issuance.
The offering is expected to close on or about Nov. 6, 2026, subject to customary closing conditions, with Canaccord Genuity acting as sole bookrunner. Annovis intends to use the net proceeds to support continued clinical development of its investigational oral therapy buntanetap for Alzheimer's disease and Parkinson's disease, as well as for working capital and general corporate purposes. The raise is significant because it provides the company with the capital needed to advance its lead drug candidate through late-stage trials, a costly and time-intensive phase that is critical for any potential regulatory approval.
Buntanetap (formerly posiphen) is a once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. The company is headquartered in Malvern, Pennsylvania, and its progress is closely watched by investors and researchers alike given the unmet need for disease-modifying treatments in neurodegenerative disorders.
The offering also includes warrants that could provide additional capital if exercised, though the company notes that the gross proceeds figure excludes potential warrant exercises and is before deducting offering expenses. For a clinical-stage biotech with no approved products, such financing is a lifeline that extends the runway for research and development. The news comes as Annovis continues to enroll patients in its Phase 3 program, and the funds are expected to support those efforts through key milestones. Investors can find more information on the company's website at www.annovisbio.com and follow updates on LinkedIn, YouTube, and X. The latest news and updates relating to ANVS are available in the company's newsroom at https://ibn.fm/ANVS.
The offering was announced through BioMedWire, a specialized communications platform focused on biotechnology and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire and other services. The full press release can be viewed at https://ibn.fm/DGBQK.
